Table 4Coronary revascularization: Prasugrel compared with clopidogrel (TRITON-TIMI 381, JUMBO-TIMI 262, PRINCIPLE-TIMI 443)

Domains pertaining to strength of evidenceMagnitude of effectStrength of evidence
Number of studies; number of subjectsRisk of bias (design/quality)ConsistencyDirectnessPrecisionHazard ratio (95% confidence interval)High, moderate, low, insufficient
All-cause mortality
1/N=136081Low (RCT/Good)UnknownDirectPrecise0.95 (0.78 to 1.16)High
2/N=11062,3Low (RCT/Fair)UnknownDirectImprecise3 prasugrel, 0 clopidogrelLow
Cardiovascular mortality
1/N=136081Low (RCT/Good)UnknownDirectImprecise0.89 (0.70 to 1.12)Moderate
2/N=11062,3NRInsufficient
Revascularization
1/N=136081Low (RCT/Good)UnknownDirectPrecise0.67 (0.55 to 0.82)aHigh
2/N=11062,3Low (RCT/Fair)UnknownDirectImprecise4 prasugrel, 7 clopidogrelLow
Major bleeding (TIMI, non-CABG related)
1/N=136081Low (RCT/Good)UnknownDirectImprecise1.32 (1.03 to 1.68)Moderate
2/N=11062,3Low (RCT/Fair)UnknownDirectImprecise11 prasugrel, 3 clopidogrelLow
Withdrawal due to adverse events
1/N=136081
2/N=11062,3
Low (RCT/Good)UnknownDirectImprecise1.14 (1.00 to 1.29)
NR
Moderate
Insufficient
a

Calculated by OR EPC using StatsDirect

From: Appendix F, Strength of evidence

Cover of Drug Class Review: Newer Antiplatelet Agents
Drug Class Review: Newer Antiplatelet Agents: Final Update 2 Report [Internet].
Ketchum K, Peterson K, Thakurta S, et al.
Portland (OR): Oregon Health & Science University; 2011 Jun.
Copyright © 2011 by Oregon Health & Science University.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.